Vanda Pharmaceuticals
VNDA
131 hedge funds and large institutions have $812M invested in Vanda Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 16 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
31% more capital invested
Capital invested by funds: $621M → $812M (+$191M)
5% more funds holding
Funds holding: 125 → 131 (+6)
3.66% more ownership
Funds ownership: 90.97% → 94.63% (+3.7%)
11% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 45
54% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $2.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$51.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$22.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$21.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.2M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.16M |
| 3 |
BlackRock
New York
|
-$5.04M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.2M |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$2.92M |
VNDA Hedge Fund Activity: Q1 2018 in Review
131 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2018, worth a combined $812M — up 31% from $621M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VNDA positions and 16 closed out — a net gain of 8 holders — while 40 added to existing stakes and 45 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $51.4M. The largest seller was OrbiMed, exiting entirely with an estimated $14.7M sold.
- 131 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2018, up from 125 in Q4 2017.
- Funds reported $812M of Vanda Pharmaceuticals stock for Q1 2018, up 31% quarter-over-quarter.
- 24 funds opened new Vanda Pharmaceuticals positions in Q1 2018 and 16 closed out, a net change of +8 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2018 was Consonance Capital Management, an estimated $51.4M added.
- The largest Vanda Pharmaceuticals seller in Q1 2018 was OrbiMed, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2018.